Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 12/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.40 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.40 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.40 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.40 |
| ▸ | CYP2F1 | P24903 | 1/20 | 0.40 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4F8 | P98187 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6970319 | 0.77 | ALDH1A1 (0.43) | CYP2E1CYP3A4CYP2D6CYP2A6CYP2C9 | |
| SCHEMBL7347251 | 0.77 | ALDH1A1 (0.43) | CYP2E1CYP3A4CYP2D6CYP2A6CYP2C9 | |
| SCHEMBL3257925 | 0.73 | RPA1 (0.41) | CYP1A1CYP1A2CYP1B1MMP13PTGS2 | |
| SCHEMBL3071920 | 0.71 | KIF11 (0.66) | KIF11MMP13PTGS2 | |
| SCHEMBL29273187 | 0.71 | KIF11 (0.68) | KIF11CYP1A1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL219153 | 0.70 | ALDH1A1 (0.48) | CYP1A2CYP2C19 | |
| SCHEMBL10222192 | 0.69 | PRMT1 (0.48) | KIF11CYP1A1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL2158436 | 0.69 | KDM4E (0.66) | KIF11CYP1A1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL2318440 | 0.69 | CYP1A1 (0.42) | KIF11CYP1A1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL28133842 | 0.68 | CYP1A1 (0.47) | KIF11CYP1A1CYP1A2CYP2E1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1373262-B1 | AZACYCLOALKYL SUBSTITUTED ACETIC ACID DERIVATIVES FOR USE AS MMP INHIBITORS | NOVARTIS AG (CH) | 2010-05-12 | — | — | EP | disclosed |
| US-20070060569-A1 | Azacycloalkyl substituted acetic acid derivatives for use as MMP inhibitors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
| US-20040235896-A1 | Certain azacycloalkyl substituted acetic acid derivatives | FUJIMOTO ROGER AKI (US) | 2004-11-25 | — | — | US | disclosed |
| EP-1373262-A2 | AZACYCLOALKYL SUBSTITUTED ACETIC ACID DERIVATIVES FOR USE AS MMP INHIBITORS | Novartis AG (CH) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002072577-A2 | AZACYCLOALKYL SUBSTITUTED ACETIC ACID DERIVATIVES FOR USE AS MMP INHIBITORS. | NOVARTIS AG (CH) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060569-A1 | Azacycloalkyl substituted acetic acid derivatives for use as MMP inhibitors | MMP9, MMP1, MMP13 | KIF11 3100/4885CYP1A1 270/4885CYP1A2 268/4885 |
| US-20040235896-A1 | Certain azacycloalkyl substituted acetic acid derivatives | MMP1, MMP9, MMP13 | KIF11 4140/4885CYP1A1 149/4885CYP1A2 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.